ELTX
- Elicio Therapeutics Inc.
()
Overview
Company Summary
Elicio Therapeutics Inc. is a biotechnology company that is focused on transforming the field of immunotherapy to treat a wide range of diseases, including cancer and autoimmune disorders. The company specializes in developing novel therapies based on its technology platform called Amphiphile Immune Modulation (AIM).
AIM is a unique approach that combines antigens with small synthetic molecules called amphiphiles to create therapeutic vaccines. These vaccines stimulate the body's immune system to recognize and attack specific disease targets, such as cancer cells or disease-causing proteins.
Elicio's technology allows for targeted delivery of antigens, ensuring that they are presented to the immune system in the most effective way possible. This approach has the potential to enhance the body's immune response and improve the outcome of immunotherapy treatments.
The company's research and development efforts are focused on developing multiple therapeutic programs across various disease indications. Elicio is actively exploring partnerships and collaborations to advance its pipeline and bring its innovative therapies to patients in need.
In summary, Elicio Therapeutics Inc. is a biotechnology company that leverages its unique Amphiphile Immune Modulation (AIM) platform to develop immunotherapies for the treatment of diseases, with a particular focus on cancer and autoimmune disorders.